News
Important Only
Toragen- Positive Safety Data From Phase 1 Trial Of Tgn-S11, In Patients With Cancers Associated With Hpv
April 15 (Reuters) - TORAGEN- POSITIVE SAFETY DATA FROM PHASE 1 TRIAL OF TGN-S11, IN PATIENTS WITH CANCERS ASSOCIATED WITH HPVTORAGEN- EVIDENCE OF ACTIVITY IS IDENTIFIED FOR TGN-S11 AS A MONOTHERAPY AND IN COMBINATION WITH KEYTRUDATORAGEN- PHASE 1 TRIAL MET BOTH PRIMARY ENDPOINTS OF PROVING SAFETY A...Reuters
Tue, Apr 15
FDA Clears Ceribell’S Clarity Algorithm For Pediatric Patients
April 15 (Reuters) - CeriBell Inc CBLL.O:FDA CLEARS CERIBELL’S CLARITY™ ALGORITHM FOR PEDIATRIC PATIENTS, MAKING CERIBELL THE FIRST AND ONLY FDA-CLEARED AI TECHNOLOGY FOR DETECTION OF ELECTROGRAPHIC SEIZURES IN PATIENTS AGES 1 YEAR AND OLDERReuters
Tue, Apr 15
Citi aiming for Banamex IPO by year-end, says regulatory delay possible
April 15 (Reuters) - Citigroup C.N is aiming to be ready for an initial public offering of its Banamex unit by the end of the year, but securing regulatory approvals could push the timeline into 2026, its CFO Mark Mason said on Tuesday.Reuters
Tue, Apr 15
Alignment Healthcare Strengthens Leadership To Scale Its Ai-Enabled Medicare Advantage Platform With Two Key Appointments
April 15 (Reuters) - Alignment Healthcare Inc ALHC.O:ALIGNMENT HEALTHCARE STRENGTHENS LEADERSHIP TO SCALE ITS AI-ENABLED MEDICARE ADVANTAGE PLATFORM WITH TWO KEY APPOINTMENTSReuters
Tue, Apr 15
Mural Oncology Announces Plans To Explore Strategic Alternatives
April 15 (Reuters) - Mural Oncology PLC MURA.O:MURAL ONCOLOGY ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVESMURAL ONCOLOGY PLC - TO EXPLORE STRATEGIC ALTERNATIVES, REDUCE WORKFORCE BY 90%MURAL ONCOLOGY PLC - NOT IN ACTIVE DISCUSSIONS WITH ANY POTENTIAL OFFERORReuters
Tue, Apr 15
Citigroup CFO Mark Mason Says We're Hoping That The 90-Day Pause On Us Tariffs Will Allow For Some Breathing Room
April 15 (Reuters) - Citigroup Inc C.N:CITIGROUP CFO MARK MASON SAYS WE'RE HOPING THAT THE 90-DAY PAUSE ON US TARIFFS WILL ALLOW FOR SOME BREATHING ROOMCITIGROUP CFO MARK MASON SPEAKS ON MEDIA CALLCITIGROUP CFO SAYS THERE'S OBVIOUSLY A GREAT DEAL OF UNCERTAINTY AROUND TARIFFS, DEREGULATION A...Reuters
Tue, Apr 15
Oak Hill Bio Enters Exclusive License Deal With Roche To Obtain Global Rights For Phase 3-Ready Treatment For Individuals With Angelman Syndrome
April 15 (Reuters) - Roche Holding AG ROG.S:OAK HILL BIO: ENTERS EXCLUSIVE LICENSE DEAL WITH ROCHE TO OBTAIN GLOBAL RIGHTS FOR PHASE 3-READY TREATMENT FOR INDIVIDUALS WITH ANGELMAN SYNDROMEOAK HILL: PLANS TO INITIATE A PHASE 3 STUDY IN EARLY 2026Reuters
Tue, Apr 15
